Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.28
IPCI's Cash to Debt is ranked lower than
91% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. IPCI: 0.28 )
Ranked among companies with meaningful Cash to Debt only.
IPCI' s Cash to Debt Range Over the Past 10 Years
Min: 0.28  Med: 10000.00 Max: No Debt
Current: 0.28
Equity to Asset -0.28
IPCI's Equity to Asset is ranked lower than
95% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IPCI: -0.28 )
Ranked among companies with meaningful Equity to Asset only.
IPCI' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.92 Max: 1
Current: -0.28
-1.36
1
F-Score: 2
Z-Score: -22.81
M-Score: -6.62
WACC vs ROIC
2.83%
-1183.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -242.31
IPCI's Operating margin (%) is ranked lower than
62% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. IPCI: -242.31 )
Ranked among companies with meaningful Operating margin (%) only.
IPCI' s Operating margin (%) Range Over the Past 10 Years
Min: -9455.14  Med: -446.56 Max: -40.29
Current: -242.31
-9455.14
-40.29
Net-margin (%) -250.21
IPCI's Net-margin (%) is ranked lower than
63% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. IPCI: -250.21 )
Ranked among companies with meaningful Net-margin (%) only.
IPCI' s Net-margin (%) Range Over the Past 10 Years
Min: -5735.51  Med: -752.78 Max: -43.97
Current: -250.21
-5735.51
-43.97
ROE (%) -555.52
IPCI's ROE (%) is ranked lower than
97% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. IPCI: -555.52 )
Ranked among companies with meaningful ROE (%) only.
IPCI' s ROE (%) Range Over the Past 10 Years
Min: -233.45  Med: -201.12 Max: -103.25
Current: -555.52
-233.45
-103.25
ROA (%) -151.50
IPCI's ROA (%) is ranked lower than
92% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. IPCI: -151.50 )
Ranked among companies with meaningful ROA (%) only.
IPCI' s ROA (%) Range Over the Past 10 Years
Min: -341.48  Med: -96.04 Max: -64.63
Current: -151.5
-341.48
-64.63
ROC (Joel Greenblatt) (%) -507.84
IPCI's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. IPCI: -507.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPCI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9016.73  Med: -833.05 Max: -235.63
Current: -507.84
-9016.73
-235.63
Revenue Growth (3Y)(%) 133.20
IPCI's Revenue Growth (3Y)(%) is ranked higher than
96% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. IPCI: 133.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPCI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 133.2
Current: 133.2
0
133.2
EBITDA Growth (3Y)(%) -33.20
IPCI's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. IPCI: -33.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPCI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.10 Max: 44.9
Current: -33.2
0
44.9
EPS Growth (3Y)(%) -17.20
IPCI's EPS Growth (3Y)(%) is ranked lower than
64% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. IPCI: -17.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPCI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.65 Max: 63.9
Current: -17.2
0
63.9
» IPCI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SBOT, NAS:RPRX, OTCPK:MTNB, OTCPK:COTXF, OTCPK:IMUN, OTCPK:VNAPF, OTCPK:TPIV, AMEX:CANF, NAS:VICL, OTCPK:ORGS, OTCPK:VGEN, NAS:PRAN, OTCPK:PMCB, OTCPK:GRSO, NAS:CBAY, NAS:BCLI, NAS:SNTA, NAS:EBIO, OTCPK:ONCYF, OTCPK:BIOAF » details
Traded in other countries:I.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.

Ratios

vs
industry
vs
history
P/S 10.77
IPCI's P/S is ranked lower than
52% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. IPCI: 10.77 )
Ranked among companies with meaningful P/S only.
IPCI' s P/S Range Over the Past 10 Years
Min: 6  Med: 21.88 Max: 4290
Current: 10.77
6
4290
Current Ratio 0.33
IPCI's Current Ratio is ranked lower than
95% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IPCI: 0.33 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 5.18 Max: 94.99
Current: 0.33
0.33
94.99
Quick Ratio 0.33
IPCI's Quick Ratio is ranked lower than
94% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. IPCI: 0.33 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 5.17 Max: 94.99
Current: 0.33
0.33
94.99
Days Sales Outstanding 31.63
IPCI's Days Sales Outstanding is ranked higher than
75% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. IPCI: 31.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 10.23 Max: 352.81
Current: 31.63
0.5
352.81
Days Payable 113.19
IPCI's Days Payable is ranked higher than
69% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. IPCI: 113.19 )
Ranked among companies with meaningful Days Payable only.
IPCI' s Days Payable Range Over the Past 10 Years
Min: 30.4  Med: 39.45 Max: 58.24
Current: 113.19
30.4
58.24

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.49
IPCI's Price/Median PS Value is ranked higher than
81% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. IPCI: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
IPCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 3.98 Max: 400
Current: 0.49
0.29
400
Earnings Yield (Greenblatt) (%) -21.34
IPCI's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. IPCI: -21.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -671.7  Med: 0.00 Max: 0
Current: -21.34
-671.7
0

More Statistics

Revenue (TTM) (Mil) $3.52
EPS (TTM) $ -0.36
Beta1.65
Short Percentage of Float6.31%
52-Week Range $1.41 - 3.87
Shares Outstanding (Mil)24.71

Analyst Estimate

Nov16 Nov17 Nov18
Revenue (Mil $) 12 57 90
EPS ($) -0.19 0.90 1.66
EPS w/o NRI ($) -0.19 0.90 1.66
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics Closes Public Offering for US$5.2 Million Jun 06 2016
Intellipharmaceutics Closes Public Offering for US$5.2 Million Jun 06 2016
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants May 27 2016
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants May 27 2016
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants May 26 2016
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants May 26 2016
Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences... May 12 2016
Intellipharmaceutics Reports Director Election Results Apr 19 2016
Intellipharmaceutics Reports Director Election Results Apr 19 2016
8 Stocks Under $10 to Trade for Big Gains Apr 17 2016
Intellipharmaceutics Announces First Quarter 2016 Results Apr 15 2016
Intellipharmaceutics Announces First Quarter 2016 Results Apr 15 2016
INTELLIPHARMACEUTICS INTERNATIONAL INC. Financials Mar 24 2016
Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor... Jan 19 2016
Intellipharmaceutics Up on Positive Rexista Oxycodone Data Jan 15 2016
These 4 Stocks are Enjoying a Green Day Jan 14 2016
IntelliPharmaCeutics Surges After Company Reports Successful Bioequivalence Results Jan 14 2016
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista™... Jan 14 2016
IntelliPharmaCeutics (IPCI) Rises: Stock Up 6.5% in Session Jan 12 2016
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)